Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Role of Sphingolipids in Pulmonary Edema (09-045)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2012 by RWTH Aachen University.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
RWTH Aachen University Identifier:
First received: July 13, 2010
Last updated: December 13, 2012
Last verified: December 2012

In this mono-center prospective study, the impact of changes in the sphingolipid metabolism in patients with pulmonary edema will be investigated.

Pulmonary Edema

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Role of Sphingolipids in Pulmonary Edema

Resource links provided by NLM:

Further study details as provided by RWTH Aachen University:

Estimated Enrollment: 70
Study Start Date: July 2010
Estimated Study Completion Date: May 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
hydrostatic pulmonary edema
patients with a pulmonary edema caused by chronic heart failure
toxic pulmonary edema
patients with a pulmonary edema preceded by pneumonia
control group
not ventilated patients without any pulmonary edema receiving a bronchoscopy due to another pulmonary problem (no pneumonia, no heart failure)

Detailed Description:

There will be three groups of patients:

  1. hydrostatic pulmonary edema
  2. toxic pulmonary edema
  3. not ventilated patients without any pulmonary edema

Samples of a routine bronchoalveolar lavage and EDTA-blood will be analysed in respect of sphingolipids, ceramide, sphingomyelin-phosphodiesterase and several cytokines.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

3 groups

first group: patients with a lung oedema because of a pneumonia (about 30 patients)

second group: patients with a lung oedema because of cardiac insufficiency (about 25 patients)

third group: patients without any lung oedema (about 15 patients)


Inclusion Criteria:

  • above the age of 18

Exclusion Criteria:

  • taking steroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01162161

Contact: Stefan Krueger, PD Dr. med. 0049-241-8085152

Medical Clinic I, University Hospital Aachen Recruiting
Aachen, Nordrhein-Westfalen, Germany, 52074
Contact: Stefan Krüger, PD Dr. med.   
Sponsors and Collaborators
RWTH Aachen University
Principal Investigator: Stefan Krüger, MD, PhD RWTH Aachen University
  More Information

No publications provided

Responsible Party: RWTH Aachen University Identifier: NCT01162161     History of Changes
Other Study ID Numbers: Sphingo-AC
Study First Received: July 13, 2010
Last Updated: December 13, 2012
Health Authority: Germany: Ethics Committee

Keywords provided by RWTH Aachen University:

Additional relevant MeSH terms:
Pulmonary Edema
Lung Diseases
Respiratory Tract Diseases processed this record on February 27, 2015